Ongoing trials of PD-1/PD-L1 inhibition in TCL
| Study name . | Study no. . | Study phase . |
|---|---|---|
| Study of pembrolizumab in patients with early-stage NK/T-cell Lymphoma, nasal type | NCT03728972 | 2 |
| Pembrolizumab and pralatrexate in treating patients with relapsed or refractory peripheral T-cell lymphomas | NCT03598998 | 1/2 |
| Pembrolizumab in relapsed or refractory extranodal NK/T-cell lymphoma, nasal type and EBV-associated diffuse large B-cell lymphomas | NCT03586024 | 1/2 |
| A trial assessing the effect of pembrolizumab combined with radiotherapy in patients with relapsed, refractory, specified stages of cutaneous T-cell lymphoma (CTCL) mycosis fungoides (MF)/Sézary syndrome (SS) (PORT) | NCT03385226 | 2 |
| Study of pembrolizumab (MK-3475) in combination with romidepsin | NCT03278782 | 1/2 |
| Study of pembrolizumab combined with decitabine and pralatrexate in PTCL and CTCL | NCT03240211 | 1 |
| Pembrolizumab and external beam radiation therapy in treating patients with relapsed or refractory non-Hodgkin lymphoma | NCT03210662 | 2 |
| Phase 2 trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (cohort 2) (NIVO-ALCL) | NCT03703050 | 2 |
| Nivolumab with standard of care chemotherapy for peripheral T-cell lymphomas | NCT03586999 | 1/2 |
| Durvalumab in different combinations with pralatrexate, romidepsin and oral 5-azacitidine for lymphoma | NCT03161223 | 1/2 |
| Durvalumab with or without lenalidomide in treating patients with relapsed or refractory cutaneous or peripheral T-cell lymphoma | NCT03011814 | 1/2 |
| PARCT: Trial of atezolizumab in relapsed/refractory cutaneous T-cell lymphoma (CTCL) (PARCT) | NCT03357224 | 2 |
| Avelumab in relapsed and refractory peripheral T-cell lymphoma (AVAIL-T) | NCT03046953 | 2 |
| Study name . | Study no. . | Study phase . |
|---|---|---|
| Study of pembrolizumab in patients with early-stage NK/T-cell Lymphoma, nasal type | NCT03728972 | 2 |
| Pembrolizumab and pralatrexate in treating patients with relapsed or refractory peripheral T-cell lymphomas | NCT03598998 | 1/2 |
| Pembrolizumab in relapsed or refractory extranodal NK/T-cell lymphoma, nasal type and EBV-associated diffuse large B-cell lymphomas | NCT03586024 | 1/2 |
| A trial assessing the effect of pembrolizumab combined with radiotherapy in patients with relapsed, refractory, specified stages of cutaneous T-cell lymphoma (CTCL) mycosis fungoides (MF)/Sézary syndrome (SS) (PORT) | NCT03385226 | 2 |
| Study of pembrolizumab (MK-3475) in combination with romidepsin | NCT03278782 | 1/2 |
| Study of pembrolizumab combined with decitabine and pralatrexate in PTCL and CTCL | NCT03240211 | 1 |
| Pembrolizumab and external beam radiation therapy in treating patients with relapsed or refractory non-Hodgkin lymphoma | NCT03210662 | 2 |
| Phase 2 trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (cohort 2) (NIVO-ALCL) | NCT03703050 | 2 |
| Nivolumab with standard of care chemotherapy for peripheral T-cell lymphomas | NCT03586999 | 1/2 |
| Durvalumab in different combinations with pralatrexate, romidepsin and oral 5-azacitidine for lymphoma | NCT03161223 | 1/2 |
| Durvalumab with or without lenalidomide in treating patients with relapsed or refractory cutaneous or peripheral T-cell lymphoma | NCT03011814 | 1/2 |
| PARCT: Trial of atezolizumab in relapsed/refractory cutaneous T-cell lymphoma (CTCL) (PARCT) | NCT03357224 | 2 |
| Avelumab in relapsed and refractory peripheral T-cell lymphoma (AVAIL-T) | NCT03046953 | 2 |